Qiagen launches QIAstat-Dx in Europe

July 2018—Qiagen announced the European launch of its QIAstat-Dx, a next-generation multiplex molecular diagnostic that provides a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology, and other diseases. The system can process up to 48 targets using real-time PCR technology and is designed with the additional capability to process immunoassays. The CE-IVD-marked platform is being launched with an upgraded CE-IVD-marked respiratory panel that detects 21 pathogens. The company plans to release the QIAstat-Dx in most countries, including the U.S., by the first half of 2019, subject to regulatory clearances.
Qiagen, 800-426-8157